Dexcom (NASDAQ: DXCM) CEO reports PSU vesting, tax-share withholding

Rhea-AI Filing Summary

Dexcom President and CEO Jacob Steven Leach reported equity compensation activity in the company’s common stock. On January 29, 2026, he received 8,310 shares at $0 upon vesting of previously granted performance-based restricted stock units, reflecting achieved performance goals.

To cover tax withholding on this vesting, 3,058 shares were withheld by Dexcom at $73.36 per share; this withholding is not a sale. After these transactions, Leach directly held 337,051 shares, plus 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust. The direct holdings include 84,537 unvested restricted stock units with various grant and future vesting dates.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Leach Jacob Steven

Role President, CEO, and Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,310	$0.00	--
Tax Withholding	Common Stock	3,058	$73.36	$224K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 340,109 shares (Direct); Common Stock — 47,296 shares (Indirect, Family Holdings)

Footnotes (1)

1. Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 102 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leach Jacob Steven

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO, and Director

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		A		8,310(1)	A	$0	340,109	D
Common Stock	01/29/2026		F		3,058(2)	D	$73.36	337,051(3)	D
Common Stock								47,296	I	Family Holdings(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs.

2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person.

3. Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 102 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

4. Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Jacob Steven Leach	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did DXCM CEO Jacob Leach report?

Dexcom CEO Jacob Leach reported 8,310 common shares received from performance-based restricted stock unit vesting and 3,058 shares withheld for taxes. These movements reflect equity compensation mechanics rather than open-market buying or selling by the executive.

How many Dexcom (DXCM) shares does Jacob Leach hold after this Form 4?

After the reported transactions, Jacob Leach holds 337,051 Dexcom common shares directly and 47,296 shares indirectly via the Gregg Family Grandchildren's Trust. His direct holdings also include 84,537 unvested restricted stock units scheduled to vest over several future dates.

Was there an actual stock sale by the DXCM CEO in this filing?

The filing shows no open-market sale by the CEO. Instead, 3,058 shares were withheld by Dexcom at $73.36 per share to satisfy tax obligations tied to vested performance units, which the disclosure states does not represent a sale by Jacob Leach.

What triggered the 8,310 Dexcom (DXCM) shares issued to Jacob Leach?

The 8,310 shares were issued upon vesting of performance-based restricted stock units granted on March 8, 2023. The vesting occurred after performance conditions under those PSUs were achieved, converting the units into Dexcom common stock for the CEO.

What unvested equity awards does DXCM CEO Jacob Leach still have?

Within his direct holdings, 84,537 unvested restricted stock units remain outstanding. These include grants from March 8, 2023, 2024, and 2025, with scheduled vesting dates extending through March 8, 2028, plus 102 shares acquired under Dexcom’s 2015 Employee Stock Purchase Plan.